🚀 VC round data is live in beta, check it out!
Molecure Valuation Multiples
Discover revenue and EBITDA valuation multiples for Molecure and similar public comparables like SoftOx Solutions, Mendus, Elicera Therapeutics, Intervacc and more.
Molecure Overview
About Molecure
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
Founded
2012
HQ
Employees
88
Website
Sectors
Financials (LTM)
EV
$26M
Molecure Financials
Molecure reported last 12-month revenue of $3M and negative EBITDA of ($5M).
In the same LTM period, Molecure generated ($5M) in EBITDA losses and had net loss of ($4M).
Revenue (LTM)
Molecure P&L
In the most recent fiscal year, Molecure reported revenue of — and EBITDA of ($8M).
Molecure expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | — | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($935K) | XXX | XXX | XXX |
| EBITDA | ($5M) | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | (167%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (199%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($4M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (135%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Molecure Stock Performance
Molecure has current market cap of $30M, and enterprise value of $26M.
Market Cap Evolution
Molecure's stock price is $1.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26M | $30M | -1.3% | XXX | XXX | XXX | $-0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMolecure Valuation Multiples
Molecure trades at 9.1x EV/Revenue multiple, and (5.4x) EV/EBITDA.
EV / Revenue (LTM)
Molecure Financial Valuation Multiples
As of April 11, 2026, Molecure has market cap of $30M and EV of $26M.
Equity research analysts estimate Molecure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Molecure has a P/E ratio of (8.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $30M | XXX | $30M | XXX | XXX | XXX |
| EV (current) | $26M | XXX | $26M | XXX | XXX | XXX |
| EV/Revenue | 9.1x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (5.4x) | XXX | (3.4x) | XXX | XXX | XXX |
| EV/EBIT | (4.6x) | XXX | (2.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (27.6x) | XXX | XXX | XXX |
| P/E | (8.0x) | XXX | (3.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Molecure Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Molecure Margins & Growth Rates
Molecure's revenue in the last 12 month grew by 190%.
Molecure's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Molecure Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 190% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (167%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (37%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Molecure Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SoftOx Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Mendus | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Intervacc | XXX | XXX | XXX | XXX | XXX | XXX |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Molecure M&A Activity
Molecure acquired XXX companies to date.
Last acquisition by Molecure was on XXXXXXXX, XXXXX. Molecure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Molecure
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMolecure Investment Activity
Molecure invested in XXX companies to date.
Molecure made its latest investment on XXXXXXXX, XXXXX. Molecure invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Molecure
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Molecure
| When was Molecure founded? | Molecure was founded in 2012. |
| Where is Molecure headquartered? | Molecure is headquartered in Poland. |
| How many employees does Molecure have? | As of today, Molecure has over 88 employees. |
| Is Molecure publicly listed? | Yes, Molecure is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Molecure? | Molecure trades under MOC ticker. |
| When did Molecure go public? | Molecure went public in 2018. |
| Who are competitors of Molecure? | Molecure main competitors are SoftOx Solutions, Mendus, Elicera Therapeutics, Intervacc. |
| What is the current market cap of Molecure? | Molecure's current market cap is $30M. |
| What is the current revenue of Molecure? | Molecure's last 12 months revenue is $3M. |
| What is the current revenue growth of Molecure? | Molecure revenue growth (NTM/LTM) is 190%. |
| What is the current EV/Revenue multiple of Molecure? | Current revenue multiple of Molecure is 9.1x. |
| Is Molecure profitable? | No, Molecure is not profitable. |
| What is the current EBITDA of Molecure? | Molecure has negative EBITDA and is not profitable. |
| What is Molecure's EBITDA margin? | Molecure's last 12 months EBITDA margin is (167%). |
| What is the current EV/EBITDA multiple of Molecure? | Current EBITDA multiple of Molecure is (5.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.